skip to primary navigationskip to content
 

Dr Alexey Larionov

Biography:

I was graduated as a medical doctor in Russia in 1992 (I.P.Pavlov State Medical University, St.Petersburg).  For several years I combined clinical work in emergency medicine and in medical oncology.  In 1998 I completed PhD in experimental oncology (N.N.Petrov Institute of Oncology, St.Petersburg, Russia).  My PhD project focused on extra-gonadal aromatase activity in breast cancer patients.  Supported by the Royal Society I did my postdoctoral fellowship in Edinburgh University.   Shortly after this I switched my clinical career in Russia to a research career in the UK.  During more than 10 years I continued research in Edinburgh University on endocrine aspects of breast cancer (see selected publications below, or the longer list at www.researcherid.com/rid/A-5088-2010 ).  Citation metrics in Sep 2015: h-index 15, average citation per paper 25 (calculated by www.researcherid.com ). 

Working with data-rich methods (qPCR & microarrays) I became interested in data analysis.  After a period of self-education in bioinformatics (mainly R-scripting for microarray projects) I completed MSc in bioinformatics (Cranfield University, 2012). In my MSc project I developed approaches for classification of endocrine resistant breast cancers from transcriptomic datasets using published multi-gene signatures (see summary at www.larionov.co.uk ).  My current work includes bioinformatics support for exome sequencing projects in heritable breast cancer (Marc Tischkowitz group, Academic Laboratory of Medical Genetics, School of Clinical Medicine, University of Cambridge). 

My career so far has been heavily biased toward research. However, I always enjoyed teaching when the opportunities arose. I supervised MSc project in Molecular Medicine in Cranfield University; I run a Clinical Pharmacology seminar for undergrads in Edinburgh University; I completed PgCert in University Teaching/ Academic Practices; and I am a Fellow of The Higher Education Academy (UK). 

Research Interests

Endocrine treatment and resistance in breast cancer

Whole exome sequencing data analysis

PCR and gene expression microarray data analysis

Teaching

Invited seminars for BSc Hon in Clinical Pharmacology (Edinburgh University, 2012 - till present; last year seminar: www.larionov.co.uk/ClinPharm2014 )

MD student supervision in Molecular Medicine (Cranfield University, 2011)

I have completed PgCert in Academic Practices and I am a Fellow of The Higher Education Academy (UK) 

Keywords

  • Genomics
  • PCR
  • Microarrays
  • Pathways
  • NGS
  • Gene Expression

Topics

  • Endocrine Resistance
  • Breast Cancer
  • Biomarkers
  • Endocrine Treatment

Key Publications

Books

A. Larionov (editor) (2015) Resistance to aromatase inhibitors in breast cancer. Springer, ISBN: 978-3-319-17971-1 (Print) 978-3-319-17972-8 (Online)

Chapters

Larionov A (in press) Novel translational research of neo-adjuvant endocrine therapy.  Chapter in Personalized Treatment of Breast Cancer. Editors: Masakazu Toi, Eric Winer, John Benson, Suzanne Klimberg.  Springer, ISBN 978-4-431-55552-0

Larionov A & Miller WR (2015) Prediction of Response to Aromatase Inhibitors in Breast Cancer.  Chapter in Resistance to Aromatase Inhibitors in Breast Cancer. Editor: Alexey A Larionov, Series: Resistance to Targeted Anti-Cancer Therapeutics.  Springer, ISBN: 978-3-319-17971-1 (Print) 978-3-319-17972-8 (Online)

Sims AH, Larionov AA, et al (2013) Use of microarray analysis to investigate EMT gene signatures. Chapter in Adhesion Protein Protocols. Editor: Amanda S. Coutts, Series: Methods in Molecular Biology, vol. 1046, 85-95. Springer, PMID: 23868583

Articles

Miller WR, Larionov A, et al. (2012) Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 12(1):10-21

Miller WR and Larionov AA (2012) Understanding the mechanisms of aromatase inhibitor resistance. Breast Cancer Res 14(1):201

Miller WR and Larionov AA (2011) Bridging the gap between translational research and clinical application. J Natl Cancer Inst Monogr 43:134-137

Miller WR and Larionov A (2011) Molecular effects of oestrogen deprivation in breast cancer. Molecular and Cellular Endocrinology 340(2):127-136

Larionov AA and Miller WR (2010) Tailoring of endocrine treatment in breast cancer. Treatment Strategies - Oncology (publication of Cambridge Research Centre) 1(1):61-67

Miller WR and Larionov A (2010) Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res. 12(4):R52

Larionov AA and Miller WR (2009) Challenges in defining predictive markers for response to endocrine therapy in breast cancer. Future Oncol 5(9):1415-1428

Miller WR, Larionov A et al (2009) Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 27(9):1382-1387

Miller WR, Larionov A et al (2007) Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genom 17(10):813-826

Larionov A et al (2005) A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 6:62

Larionov A et al (2003) Aromatase in skeletal muscle. J Steroid Biochem Mol Biol 84(4): p. 485-492

Larionov A et al (2002) Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. J Steroid Biochem Mol Biol 81(1): p. 57-64.

Berstein LM, Larionov AA et al (1996) Aromatase in breast cancer tissue--localization and relationship with reproductive status of patients. J Cancer Res Clin Oncol. 122(8):495-8.